The whole House will have been deeply saddened by the passing of Lord Molyneaux of Killead. James Molyneaux was a distinguished second world war veteran and a fine parliamentarian who served Northern Ireland with great distinction for more than four decades, both in this House and the other place.

We are committed to ensuring the maximum transparency in party funding in Northern Ireland that the prevailing security situation allows, and progress has been made in detailed discussions with the Electoral Commission on finalising the new arrangements. I have spoken with the electoral commissioner, and I am confident that the necessary draft legislation will be ready to lay early in the next Parliament.

First, let me join the hon. Lady in praising the Titanic exhibition, which I have been to see myself. It is an absolutely brilliant visitor attraction and yet another reason to visit Belfast, and not only for people from across our United Kingdom, but for people from across Europe and around the world. I agree that what matters now is implementing the Stormont House agreement. Everyone should do what they signed up to do in that agreement, including Sinn Fein. I know that my right hon. Friend the Secretary of State for Northern Ireland is working very hard to try to ensure that everyone fulfils their pledges.

The hon. Lady is right that during the passage of the Act we discussed a review of the security situation and amending the measure accordingly. It is our aspiration to have full transparency in Northern Ireland, as we do in Great Britain. At the moment, our judgment is that the security situation does not warrant it and that we cannot take that risk, but we will keep the matter under constant review.

I say to the hon. Lady—I think we are in absolute agreement on this—that we have to break down the barriers between communities. That is what the shared future agenda is all about. The Stormont House agreement should make that move faster. We are beginning to see shared campuses for education institutions in Northern Ireland, but we now need to see the sorts of things that she is talking about, such as shared approaches on teacher training, that can reduce costs and deliver a better service. That is what the agreement should be about.

DFID regularly monitors the security and humanitarian situation in CAR. High levels of violence continue across the country, and a million people have been displaced since December 2013. The security situation impacts not only communities but humanitarian workers. The Office for the Coordination of Humanitarian Affairs (OCHA) has reported 142 security incidents directed at humanitarian workers since January 2014 and 18 humanitarian workers killed. In 2014 DFID provided £18 million to the ICRC, UN agencies and international NGOs to support communities who have suffered from the violence in CAR.

We welcome the leadership of the EU on the humanitarian response in CAR and on programmes linking relief, recovery and development. The UK is not a current contributor to the EU Trust Fund in CAR. The UK has committed £33 million in humanitarian funds to CAR and CAR refugees since July 2013, funding a range of NGOs and UN agencies to provide protection, water, health and food security.

I very much agree with the hon. Lady. The key to success in getting a sensible outcome for a new post-2015 framework is to ensure that it is not a shopping list, but that it actually works as an overall strategy to bring change on the ground and lift people out of poverty over the next 15 years.

The UK plays a leading role internationally at the EU and UN and bilaterally to push for an ambitious and implementable post-2015 framework. As the hon. Member for Feltham and Heston (Seema Malhotra) will know, the first session of intergovernmental negotiations on the SDGs has concluded, and the open working group proposal includes 17 goals and 169 targets. We support the breadth and balance of the proposal but will be arguing for a much more concise and workable agenda as negotiations progress.

As I said, one way to do that would be to take burdens off the PSNI’s shoulders by implementing the NCA. Continued focus on trying to resolve parading disputes is also important, given their potential impact on police resources. It is crucial that we get the new institutions on the past up and running as soon as possible to provide that relief to PSNI funding, and, as we discussed in the House yesterday, we need to consider whether any of the £150 million for dealing with the past can be deployed prior to the establishment of the HIU to help on these matters for the PSNI.

The UK actively pushes for the release of all political prisoners in Burma. The most recent official figures from the government of Burma suggest that 27 political prisoners remain in prison, having dropped from over 2,000 in 2011. However these figures are contested, and a leading local non-government organisation – the Assistance Association for Political Prisoners (Burma) – suggest that as of January there are 160 political prisoners with another 203 facing trial.

Clearly, the UK is very concerned by the increase in political prisoners witnessed over the last year. Officials from our Embassy in Rangoon meet regularly with members of civil society on this issue, and we continue to raise our concerns with the government of Burma at Ministerial level. I raised our concerns over political prisoners with Deputy Foreign Minister Thant Kyaw in June 2014. Most recently, the Minister of State at the Home Office, my right hon. Friend the Member for Hornsey and Wood Green (Ms Featherstone), raised this issue directly with the Minister for the President’s Office, U Soe Thein, during her visit to Burma this month. We continue to lobby on individual cases. We also raise our concerns publicly in our Annual Report on Human Rights and in multilateral fora such as the UN General Assembly, where the UK co-sponsored a Resolution last year that called for the unconditional release of all political prisoners.

DFID has already disbursed £5 million of the £20 million early recovery assistance that we pledged at the Gaza Reconstruction Conference. The UK was also the first donor to support the temporary Gaza Reconstruction Mechanism which is facilitating the import of construction materials into Gaza, and, in close co-ordination with our EU partners and the Office of the Quartet Representative, we continue to press the Government of Israel to lift restrictions and facilitate the entry of aid into Gaza.

It remains my view that the inquiry chaired by Sir Anthony Hart is the best forum to consider the allegations surrounding Kincora.

As you may be aware the Attorney General for England and Wales has written to the Chairman of the Inquiry and provided an undertaking in the usual format about the admissibility and use of evidence given by a witness who co-operates with the Inquiry. This undertaking covers any offences arising under the Official Secrets Act.

It remains my view that the Inquiry chaired by Sir Anthony Hart is the best forum to consider the allegations surrounding Kincora.

Since the launch of the Early Access to Medicines Scheme in April 2014, three Promising Innovative Medicine (PIM) designations have already been granted. By 9 January 2015 there had been 428 downloads of the PIM designation form and 187 downloads of the scientific opinion form, which indicates the high level of interest in the scheme.

The Early Access to Medicines Scheme already has a number of incentives for pharmaceutical companies. The PIM designation provides an early indication that a product may be a possible candidate for the Early Access to Medicines Scheme and is of particular value to smaller companies because it will act as a signal to potential investors. At the next stage of scientific review, the Medicines and Healthcare products Regulatory Agency will consider the evidence and can issue an Early Access to Medicines scientific opinion. This opinion will support the prescriber to make a decision with the patient on using this medicine, when still unlicensed or used off-label. Earlier clinical use of new innovative medicines will also provide valuable real world data to companies for use in subsequent health technology appraisal processes.

We committed to review the Early Access to Medicines Scheme when we launched the scheme in April 2014. Through the Innovative Medicine and Medical Technologies Review we will also be taking forward a major review over the coming months to make recommendations to Government on opportunities to accelerate access for National Health Service patients to innovative medicines, devices and diagnostics.

Off-patent drugs are those whose patent period has expired and consequently manufacturers may make available generic or non-branded versions of the products.

An “off-label” medicine is any medicine prescribed outside the terms of its licence (as set out in the prescribing information in the Summary of product Characteristics). Medicines legislation permits prescribers to prescribe a product outside the terms of its licence where they judge it to be in the best interests of the patient to address a medical need. For example to prescribe for a different use or to different category of patients but in doing so the prescriber takes personal responsibility for the treatment, inform the patient(s) of the licensing status of the product and obtain consent from the patient for its use.

The Early Access to Medicines Scheme (EAMS) aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need. Under the scheme, the Medicines and Healthcare products Regulatory Agency (MHRA) will provide a scientific opinion on the benefit/risk balance of the medicine, based on the data available at the time of the EAMS submission. The scheme is voluntary and as such the MHRA is dependent on companies submitting potential products that may fulfil the EAMS criteria.

In the government response to the public consultation, it was confirmed that off-label supply of existing medicines would be eligible for the scheme, but only if they meet the EAMS criteria. Thus companies can submit an application to the EAMS for a new indication for an already marketed drug (which may be off patent).

In developing our response to the Bill, we have taken advice from a number of cancer clinicians including breast cancer specialists and from officials at the National Institute for Health and Care Excellence, the Medicines and Healthcare products Regulatory Agency, and taken account of views expressed by other stakeholder organisations.

In June 2013 the National Institute for Health and Care Excellence (NICE) issued an updated clinical guideline on familial breast cancer which includes recommendations on the use of tamoxifen and raloxifene outside their licensed indications for the prevention of cancer in specific groups of women at high and moderate risk of breast cancer.

NICE’s clinical guidelines represent best practice and we expect commissioners to take their recommendations into account when designing services and making commissioning decisions for their healthcare population.

Our assessment is that, as NICE has already provided guidance on the use of tamoxifen and raloxifene, there would be little value in NICE separately appraising these drugs for the prevention of breast cancer and we have had no discussions with NICE on this issue.